title: Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013.
abstract: To assess changes in the clinical characteristics and treatment patterns of patients with newly diagnosed type 2 diabetes (T2D), the electronic health record system at Cleveland Clinic was used to create cross-sectional summaries of all patients with new-onset T2D in 2008 and 2013. Differences between the 2008 and 2013 data sets were assessed after adjusting for age, gender, race, and income. Approximately one-third of patients with newly diagnosed T2D in 2008 and 2013 had an A1C ≥8%, suggesting the continued presence of a delayed recognition of the disease. Patients with newly diagnosed T2D in 2008 were older than those in 2013. Hypertension, cardiovascular disease, and neuropathy were highly prevalent among patients diagnosed with T2D. The prevalence of neuropathy, cerebrovascular disease, and peripheral vascular disease increased from 2008 to 2013. Metformin was the most commonly prescribed antidiabetic medication. Sulfonylurea usage remained unchanged, while use of thiazolidinediones decreased considerably.
authors.affiliation: Endocrinology, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Pantalone
authors.affiliation: Diabetes, Novo Nordisk Inc., Plainsboro, NJ, USA.
authors.forename: Todd M
authors.initials: TM
authors.lastname: Hobbs
authors.affiliation: Translational Science Institute, Wake Forest School of Medicine, Winston-Salem, NC, USA.
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Wells
authors.affiliation: Health Economics and Outcomes Research, Novo Nordisk Inc., Plainsboro, NJ, USA.
authors.forename: Sheldon X
authors.initials: SX
authors.lastname: Kong
authors.affiliation: Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Kattan
authors.affiliation: Health Economics and Outcomes Research, Novo Nordisk Inc., Plainsboro, NJ, USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Bouchard
authors.affiliation: Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Chagin
authors.affiliation: Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Changhong
authors.initials: C
authors.lastname: Yu
authors.affiliation: Medical Affairs, Novo Nordisk Inc., Plainsboro, NJ, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Sakurada
authors.affiliation: Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Alex
authors.initials: A
authors.lastname: Milinovich
authors.affiliation: Health Economics and Outcomes Research, Novo Nordisk Inc., Plainsboro, NJ, USA.
authors.forename: Wayne
authors.initials: W
authors.lastname: Weng
authors.affiliation: Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Janine M
authors.initials: JM
authors.lastname: Bauman
authors.affiliation: Endocrinology, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Zimmerman
keywords: antidiabetic therapy; complications; diabetes; electronic health records; incidence; treatment